<DOC>
	<DOCNO>NCT01980849</DOCNO>
	<brief_summary>To compare efficacy safety prophylaxis venous thromboembolism Nadroparin hospitalization long-term usage patient advance lung cancer treat chemotherapy and/or radiotherapy .</brief_summary>
	<brief_title>Prophylaxis Venous Thromboembolism Advanced Lung Cancer</brief_title>
	<detailed_description>This prospective , multi-center , randomize control study . Advanced lung cancer patient without venous thromboembolism ( VTE ) include . The selected patient randomize A B group . Group A : Nadroparin give hospitalization , 0.4mL , subcutaneously , qid ; Group B : Nadroparin give long-term , 0.4mL , subcutaneously , qid . The incidence VTE , risk bleed overall survival two group patient study different time point .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>Stage Ⅲ B Ⅳ nonsmall cell lung cancer patient inoperable small cell lung cancer patient Performance status score ≤ 2 Chest CT measurable lesion Examination reveal part venous thromboembolism Chemotherapy regimens contain bevacizumab Endostar Severe coagulopathy Active bleed within two week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Nadroparin</keyword>
	<keyword>venous thromboembolism prophylaxis</keyword>
</DOC>